ES2087337T3 - Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos. - Google Patents

Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos.

Info

Publication number
ES2087337T3
ES2087337T3 ES92107278T ES92107278T ES2087337T3 ES 2087337 T3 ES2087337 T3 ES 2087337T3 ES 92107278 T ES92107278 T ES 92107278T ES 92107278 T ES92107278 T ES 92107278T ES 2087337 T3 ES2087337 T3 ES 2087337T3
Authority
ES
Spain
Prior art keywords
biologically active
peptide
polypeptide
active protein
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92107278T
Other languages
English (en)
Spanish (es)
Inventor
William David Steber
Susan Mancini Cady
David Farley Johnson
Theresa Rice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2087337T3 publication Critical patent/ES2087337T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/07—Stiffening bandages
    • A61L15/10—Stiffening bandages containing organic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Prostheses (AREA)
ES92107278T 1991-06-24 1992-04-29 Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos. Expired - Lifetime ES2087337T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71989891A 1991-06-24 1991-06-24

Publications (1)

Publication Number Publication Date
ES2087337T3 true ES2087337T3 (es) 1996-07-16

Family

ID=24891827

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92107278T Expired - Lifetime ES2087337T3 (es) 1991-06-24 1992-04-29 Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos.

Country Status (24)

Country Link
EP (1) EP0523330B1 (en:Method)
JP (1) JP3597205B2 (en:Method)
KR (1) KR100221031B1 (en:Method)
CN (1) CN1050301C (en:Method)
AT (1) ATE135565T1 (en:Method)
AU (1) AU656200B2 (en:Method)
BR (1) BR9202374A (en:Method)
CA (1) CA2071757C (en:Method)
DE (1) DE69209173T2 (en:Method)
DK (1) DK0523330T3 (en:Method)
ES (1) ES2087337T3 (en:Method)
GE (1) GEP19970992B (en:Method)
GR (1) GR3019457T3 (en:Method)
HU (1) HU217547B (en:Method)
IE (1) IE74398B1 (en:Method)
IL (1) IL102287A (en:Method)
LV (1) LV11816B (en:Method)
MD (1) MD1394G2 (en:Method)
MX (1) MX9203175A (en:Method)
RU (1) RU2080119C1 (en:Method)
SG (1) SG47955A1 (en:Method)
TW (1) TW215058B (en:Method)
UA (1) UA26137C2 (en:Method)
ZA (1) ZA924613B (en:Method)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
BR9912275A (pt) 1998-07-20 2001-04-17 Peptech Ltd Formulação de bioimplante
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
JP2001058955A (ja) * 1999-06-17 2001-03-06 Inst Of Physical & Chemical Res 生理活性ペプチド徐放性製剤
KR20080011353A (ko) 2000-02-24 2008-02-01 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
MXPA03000073A (es) 2000-06-26 2003-09-25 Monsanto Technology Llc Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina.
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
JP4931282B2 (ja) * 2000-10-02 2012-05-16 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
DE10161078A1 (de) * 2001-12-12 2003-08-28 Achim Goepferich Matrizes zur Stabilisierung und kontrollierten Freisetzung von Problemarzneistoffen
SE526959C2 (sv) * 2003-10-02 2005-11-29 Tikomed Ab Bioartificellt implantat innefattande en semipermeabel barriär samt förfarande för reducering av risken för bildning av bindrväv vid implantatet efter implantering genom att barriären förses med en permeabel beläggning av bioaktiv metall
JP2005145821A (ja) * 2003-11-11 2005-06-09 Kao Corp 打錠製剤
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
PE20121799A1 (es) 2009-12-21 2013-01-02 Ambrx Inc Polipeptidos de somatotropina porcina modificados y sus usos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271113A (en) * 1978-04-17 1981-06-02 Alza Corporation Process for forming a passageway in an osmotic device
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
US4863736A (en) * 1987-03-16 1989-09-05 Monsanto Company Somatotropin prolonged release
US4795644A (en) * 1987-08-03 1989-01-03 Merck & Co., Inc. Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins
WO1992002211A1 (en) * 1990-08-09 1992-02-20 Endocon, Inc. Multiple drug delivery system

Also Published As

Publication number Publication date
IL102287A0 (en) 1993-01-14
GR3019457T3 (en) 1996-06-30
TW215058B (en:Method) 1993-10-21
RU2080119C1 (ru) 1997-05-27
DE69209173T2 (de) 1996-11-28
KR930000131A (ko) 1993-01-15
ZA924613B (en) 1993-03-31
CA2071757C (en) 2003-06-10
CN1068965A (zh) 1993-02-17
GEP19970992B (en) 1997-11-20
CA2071757A1 (en) 1992-12-25
MX9203175A (es) 1993-04-01
LV11816A (lv) 1997-08-20
AU1847092A (en) 1993-01-07
UA26137C2 (uk) 1999-06-07
DK0523330T3 (da) 1996-04-15
KR100221031B1 (ko) 1999-09-15
CN1050301C (zh) 2000-03-15
SG47955A1 (en) 1998-04-17
MD1394G2 (ro) 2000-11-30
HU9202092D0 (en) 1992-09-28
AU656200B2 (en) 1995-01-27
MD1394F2 (en) 2000-01-31
IE922020A1 (en) 1992-12-30
MD940370A (en) 1996-06-28
HU217547B (hu) 2000-02-28
JPH05186363A (ja) 1993-07-27
BR9202374A (pt) 1993-01-26
ATE135565T1 (de) 1996-04-15
HUT61486A (en) 1993-01-28
EP0523330A1 (en) 1993-01-20
IL102287A (en) 2000-06-01
DE69209173D1 (de) 1996-04-25
LV11816B (en) 1997-12-20
JP3597205B2 (ja) 2004-12-02
EP0523330B1 (en) 1996-03-20
IE74398B1 (en) 1997-07-30

Similar Documents

Publication Publication Date Title
FI101938B1 (fi) Polypeptidijohdannaisia
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
PT97160A (pt) Processo para a preparacao de composicoes estaveis para administracao parenterica contendo uma proteina, peptideo ou polipeptideo biologicamente activo
ZA941771B (en) Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
DE3585556D1 (de) Pharmazeutische zusammensetzungen, welche ein dipeptid enthalten.
NZ227787A (en) Peptides and compositions having growth hormone regulatory effects
NO952744D0 (no) Cytokinbegrensende midler
FI954978A0 (fi) Modifioidut proteiini- ja peptidilääkeaineet
ES2087337T3 (es) Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos.
PT792287E (pt) Analogos peptidicos da proteina basica da mielina humana
MX9200709A (es) Activacion mejorada de proteinas recombinadas. activacion mejorada de proteinas recombinadas.
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
DE69520475D1 (de) Pharmaceutische Zusammensetzung von biologisch aktiven Peptiden oder Proteinen
SE9604593D0 (sv) Antimicrobially active polypeptides
ATE225806T1 (de) D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
FI934588A7 (fi) Ihmisen luusta johdettu insuliinin kaltainen kasvutekijää sitova prote iini
ATE93527T1 (de) Peptide und deren benutzung.
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
DE3869939D1 (de) Biologisch wirksame peptide.
EP0723016A3 (en) Leukocyte activation factor
DE69420044D1 (de) Blutregulierende peptide
CO4230067A1 (es) Composicion cosmetica para el cuidado de la piel
AR005791A1 (es) Proteina de hormona del crecimiento humano mutante; desoxirribo-nucleotido que la codifica; peptido de dicha proteina; plasmido de expresion deldesoxirribonucleotido; producto generado por las celulas transformadas por el anterior; anticuerpo y medicamento que contiene la proteina o el
ATE81531T1 (de) Biologisch aktive peptide tan-866.
NO893572D0 (no) Lunge-overflateaktivt protein og beslektet polypeptid.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 0523330

Country of ref document: ES